Skip to content

A clinical study based on metabolomics to explore the progression of infarct core after reperfusion therapy in acute ischemic stroke

A clinical study based on metabolomics to explore the progression of infarct core after reperfusion therapy in acute ischemic stroke

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300070650
Enrollment
Unknown
Registered
2023-04-19
Start date
2023-04-30
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stroke

Interventions

Ischemic semi-dark zone progression group:N/A
Non-ischemic semi-dark zone progression group:N/A

Sponsors

The First Affiliated Hospital of Wannan Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Adult (18 years or older). 2. ASPECTS score >=6 confirmed by the most recent brain tissue imaging after onset 3. clinically confirmed acute ischemic stroke in the anterior circulation with acute occlusion of the responsible vessel located in the intracranial segment of the internal carotid artery, the T bifurcation or the M1 segment of the middle cerebral artery. 4. mRS score < 2 before onset 5. time from onset to groin puncture < 24 hours 6. successful reperfusion (expanded Thrombolysis in Cerebral Infarction score 2c-3 (eTICI 2c-3)) 7. Informed consent signed by the patient himself or by the patient's legally authorized representative.

Exclusion criteria

Exclusion criteria: 1. Intracranial hemorrhagic disease as seen on cranial CT: hemorrhagic stroke, epidural hematoma, subdural hematoma, ventricular hemorrhage, subarachnoid hemorrhage, etc. 2. Known recent or current serum creatinine exceeding 1.5 times the upper limit of normal or an estimated glomerular filtration rate (eGFR) 38.0 degree, elevated white blood cells, diagnosis of pneumonia, and urinary tract infection at presentation or admission. 4. Patients with severe mental disorders or unable to cooperate in completing the informed consent and follow-up components due to dementia. 5. Patients with concurrent malignancy or with severe systemic disease with an expected survival of less than 90 days. 6. those who have participated in other interventional clinical studies within 30 days, or are participating in other interventional clinical studies postoperatively lost to follow-up

Design outcomes

Primary

MeasureTime frame
Thrombosis metabolomics;Blood Metabolomics;Volume of ischemic semidark band;

Secondary

MeasureTime frame
90-day neurological prognosis;Symptomatic intracranial hemorrhage;Deaths within 90 days;NIHSS score;GCS score;ASPECTS score;ASPECTS score;

Countries

China

Contacts

Public ContactXianjun Huang

The First Affiliated Hospital of Wannan Medical College

doctorhuangxj@hotmail.com+86 18130333940

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Sep 10, 2026